PMID- 16391399
OWN - NLM
STAT- MEDLINE
DCOM- 20060329
LR  - 20181113
IS  - 1080-0549 (Print)
IS  - 1080-0549 (Linking)
VI  - 29
IP  - 3
DP  - 2005 Dec
TI  - Intravenous immunoglobulin therapy in vasculitis: speculation or evidence?
PG  - 237-45
AB  - Initially, intravenous immunoglobulins (IVIgs) were used as replacement therapy 
      in primary and secondary antibody-deficiency syndromes. The clinical use of IVIg 
      has been extended during the past decade to a wide variety of clinical 
      conditions, such as infectious processes, neuroimmunological diseases, and 
      different systemic autoimmune diseases. The mode of action of IVIg is complex, 
      involving modulation of the Fc receptors, interference with the complement and 
      cytokine network, and effects on the activation and differentiation of T and 
      B-cells. Kawasaki disease (KD) was one of the first diseases within the group of 
      primary vasculitides in which IVIg were used. Today, there is a clear evidence of 
      benefit for IVIg in the treatment of coronary artery abnormalities related to KD. 
      Subsequently, various reports have suggested a beneficial effect in other 
      vasculitides; however, there are few data from controlled studies. For 
      antineutrophil cytoplasmic antibody-associated vasculitis (AAV) one 
      placebo-controlled and several open-label studies have shown a beneficial effect 
      on the disease activity in patients with Wegener's granulomatosis or microscopic 
      polyangiitis refractory to standard therapy with prednisone and cyclophosphamide. 
      For other vasculitides, such as polyarteritis nodosa or Henoch-Schonlein purpura, 
      only case reports have described an inhibition of a disease progression by IVIg 
      so far. However, the effect was partly only temporary. In conclusion, KD and AAV 
      are the only vasculitides with a definite beneficial use of IVIg. For other 
      vasculitides, the efficacy of IVIg has not been proven properly but may be useful 
      in single cases.
FAU - Aries, Peer Malte
AU  - Aries PM
AD  - Department of Rheumatology, University Hospital of Schleswig-Holstein, Campus 
      Luebeck, Luebeck, Germany. aries@rheuma-zentrum.de
FAU - Hellmich, Bernhard
AU  - Hellmich B
FAU - Gross, Wolfgang Ludwig
AU  - Gross WL
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Clin Rev Allergy Immunol
JT  - Clinical reviews in allergy & immunology
JID - 9504368
RN  - 0 (Antibodies, Antineutrophil Cytoplasmic)
RN  - 0 (Immunoglobulins, Intravenous)
SB  - IM
MH  - Antibodies, Antineutrophil Cytoplasmic/immunology
MH  - Clinical Trials as Topic
MH  - Humans
MH  - Immunoglobulins, Intravenous/immunology/*therapeutic use
MH  - Mucocutaneous Lymph Node Syndrome/complications/drug therapy/immunology
MH  - Vasculitis/*drug therapy/etiology/immunology
RF  - 53
EDAT- 2006/01/05 09:00
MHDA- 2006/03/30 09:00
CRDT- 2006/01/05 09:00
PHST- 2006/01/05 09:00 [pubmed]
PHST- 2006/03/30 09:00 [medline]
PHST- 2006/01/05 09:00 [entrez]
AID - CRIAI:29:3:237 [pii]
AID - 10.1385/CRIAI:29:3:237 [doi]
PST - ppublish
SO  - Clin Rev Allergy Immunol. 2005 Dec;29(3):237-45. doi: 10.1385/CRIAI:29:3:237.